Sunitinib therapy for melanoma patients with KIT mutations

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1457-1463

  Minor, David R ^a   Kashani Sabet, Mohammed ^a   Garrido, Maria ^b   O'Day, Steven J ^c   Hamid, Omid ^c   Bastian, Boris C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEM CELL FACTOR RECEPTOR; SUNITINIB;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG EFFECT; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GNAQ GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE C KIT; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RECURRENT CANCER; SKIN CANCER; SURVIVAL TIME; TREATMENT DURATION; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857760658     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1987     Document Type: Article

References (25)

1. Curtin JA, Busan K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24: 4340-6. (Pubitemid 46630793)
2. Smalley KSM, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009;24:643-50.
3. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130:20-7.
4. Demetri GD, Oosterom AT, Garrett C, Blackstein ME, Shah MH, Vderweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
5. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8.
6. Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R. Anal mucosal melanoma with KIT-activating mutations and response to imatinib therapy-case report and review of the literature. Dermatology 2010;220:77-81.
7. Hodi FS, Friedlander P, Corless CL, Heinrich MC, MacRae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.
8. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726.
9. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigmented Cell Melanoma Res 2008;21:492-3. (Pubitemid 351990966)
10. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
11. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in melanoma. JAMA 2011;305:2327-34.
12. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96. (Pubitemid 350002890)
13. Heinrich MC, Corless CL, Demetri GD, Blanke CD, vonMehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-9. (Pubitemid 46621810)
14. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi. Nature 2009;457:599-602.
15. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230-4.
16. Zhu Y, Si L, Kong Y, Chi Z, Yuan X, Cui C, et al.Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 27, 2009 (suppl; abstr e20017).
17. Decoster L, Neyns B, Vande Broek I, Anckaert E, De Clerk D, De Mey J, et al. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. J Clin Oncol 28:15s, 2010 (suppl; abstr 8518).
18. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/ mucosal type. Mod Pathol 2009;22:1446-56.
19. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010;23:210-5.
20. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, et al. Activity of dasatinib against L567P KIT mutant melanoma: molecular, cellular, and clinical coordinates. Mol Cancer Ther 2009;8: 2079-85.
21. Fruehauf JP, Lutzky J, McDermott DF, Brown CK, Pithavala YK, Bycott PW, et al. Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 9006).
22. O'Day SJ, Kim KB, Sosman JA. BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatiin and paclitaxel in previously untreated Advanced Melanoma. Eur J Cancer Suppl 2009;7:Abstract 23LBA.
23. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V660E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
24. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, et al. Large scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91.
25. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998;83:1664-78. (Pubitemid 28465486)